Ignyta Priced, Nasdaq: RXDX.XXX
Clinical-stage biotech developing targeted cancer therapeutics.
Industry: Health Care
First Day Return: +11.5%
Industry: Health Care
RXDX.XXX
Clinical-stage biotech developing targeted cancer therapeutics.
| IPO Data | |
|---|---|
| IPO File Date | 02/28/2014 |
| Offer Price | $9.15 |
| Price Range $9.15 - $9.15 | |
| Offer Shares (mm) | 5.2 |
| Deal Size ($mm) | $48 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 03/13/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $48 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | San Diego, CA, United States |
| Founded | 2011 |
| Employees at IPO | 17 |
| Website www.ignyta.com | |
IPO News for Ignyta
Ignyta (RXDX.XXX) Performance
